Drug Type Small molecule drug |
Synonyms NK2152 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization NiKang Therapeutics, Inc.Startup |
Active Organization- |
Inactive Organization NiKang Therapeutics, Inc.Startup |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Renal Cell Carcinoma | Phase 2 | US | NiKang Therapeutics, Inc.Startup | 19 Nov 2021 |